Merck , known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SCtm (pembrolizumab injection), a new subcutaneous formulation of pembrolizumab, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results